Azienda Ospedaliero-Universitaria Careggi

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Evidence to guide the treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with...

Decoding the causes of ischemic stroke despite ongoing oral anticoagulation and their clinical impact: the ASPERA-R study

BACKGROUND: Oral anticoagulants (OACs), including vitamin K antagonists and direct OACs, reduce stroke risk in atrial fibrillation (AF), yet breakthrough ischemic stroke still occurs in 1-2% of patients annually despite adequate therapy. The mechanisms underlying these events rem...

Multidisciplinary Delphi consensus-based recommendations on the use of image-guided radiotherapy for upper gastrointestinal tumours: an AIRO–AITRO–AIFM study

Abstract Objectives Upper gastrointestinal (GI) malignancies represent one of the most challenging scenarios for image-guided radiotherapy (IGRT). Despite technological advances, clinical practice remains heterogeneous among centres. This national, multidisciplinary Delphi consen...

Endovascular Thrombectomy for Cerebral Venous Thrombosis: Current Status and Future Directions

Abstract Cerebral venous thrombosis (CVT) represents a relatively rare cause of stroke, yet it carries an overall rate of death or dependency of up to 15%. The mainstay of its management is therapeutic anticoagulation, either subcutaneously or intravenously in the acute phase, fo...

Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice

Acoramidis, an oral transthyretin stabilizer that achieves near-complete stabilization, is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on the phase 3 study, ATTRibute-CM (NCT03860935). To complement trial data, ACO-REAL (NCT07235462) was des...